Talaporfin

LS 11, LS11, ME 2906, Mono-L-Aspartyl Chlorin e6, NP e6, NPE 6, Taporfin Sodium

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

Kostenich GA, Zhuravkin IN, Zhavrid EA. Chlorin-E(6) pharmacokinetics, toxicity and antitumor efficiency in photodynamic treatment of Wistar rats with sarcoma-M-1. Eksperimentalnaya Onkologiya. 15: 64–69, No. 5, 1993.
Google Scholar
Taber SW, Fingar VH, Coots CT, Wieman TJ. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a phase I clinical study. Clinical Cancer Research 4: 2741–2746, Nov 1998.
PubMed CAS Google Scholar
Song L-MWK, Wang KK, Zinsmeister AR. Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy admininstered to a human cholangiocarcinoma model. Cancer 82: 421–427, 15 Jan 1998
Article CAS Google Scholar
McMahon KS, Wieman TJ, Moore PH, et al. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response. Cancer Research 54: 5374–5379, 15 Oct 1994
PubMed CAS Google Scholar

Talaporfin. Drugs in R&D 4, 69–71 (2003). https://doi.org/10.2165/00126839-200304010-00014

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.